TechnoPhage, SA - From science to innovative biopharmaceuticals
COVID-19 New Challenge: joint effort to mitigate world’s pandemic crisis (TechnoPhage S.A., Faculty of Pharmacy of University of Lisbon and Vector B2B – Drug Developing Association for Research in Biotechnology) In Portugal, we have highly qualified human resources working in biological drug discovery and development. In a joint effort to tackle COVID-19 we…
COVID-19 patients suffering from severe forms of the disease are at risk of developing bacterial healthcare-associated infections, such as ventilator-associated pneumonia caused by multidrug resistant pathogens. TP-122 bacteriophage cocktail may be an alternative for such patients, because it consists of a biological therapeutic developed for the treatment of pneumonia caused by Pseudomonas aeruginosa,…
TechnoPhage is currently looking for a Head of Neuroscience/Ophthalmology (PhD) with a strong scientific background to lead a team dedicated to characterize and understand the function of therapeutics against a large range of targets. Click here to know more.
Technophage S.A., in collaboration with a team led by Leonor Saúde, Principal Investigator of the Instituto de Medicina Molecular João Lobo Antunes (iMM), developed a simple, fast and efficient zebrafish screening platform to discover and select new therapeutics for spinal cord injuries. This study that was published today in the Scientific Reports journal…

2019 events

Phage Futures Europe
Brussels, Belgium, September 25-26, 2019